Vasculitis & polymyalgia rheumatica
Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis
Authors' conclusion
Immunosuppressive treatments can reduce arterial wall thickness and widen lumen diameter in TAK. bDMARDs seem to be more effective than cDMARDs to improve arterial lesions in TAK.
Study context
- Population
- TAK patients followed with the same CT angiography modalities; 1–3 target vessels with wall thickening and/or stenosislines of therapy
- Participants
- 75 patients
- Exposure
- bDMARD vs csDMARD lines of therapy in TAK
- bDMARDsn = 35
- cDMARDsn = 40reference
- Outcome
- Evolution of vascular lesions (vessel wall thickness and lumen diameter) on CT angiography
- Follow-up
- 12 months
Methodological detailsCT angiography follow-up, linear mixed effects model
- CT angiography follow-up
- Linear mixed effects model
Main finding
As reported in the abstract
Vessel wall thickness reduction
- Overall reduction in arterial wall thickness
- 73%
- >25% relative decrease in wall thickness
- 31%
- First-line immunosuppressive therapy independently associated with wall thickness reduction
- P = 0.012
Observational data: associations, not effects.
Further findings
>25% relative increase in lumen diameter of stenotic vessels · 12 months
- >25% relative increase in lumen diameter of stenotic vessels — Overall, under immunosuppressive therapy
- 38%
Original publication
Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis. Rheumatology (Oxford). Published 5 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →